---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-013975"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:17:38.592825+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma reports positive Phase 2 interim efficacy for ENV105 in mCRPC; median PFS >13 months

## Summary
- Median PFS >13 months in 8 evaluable patients with mCRPC who failed prior hormone therapy.
- 5 of 8 patients continuing without progression; 7 of 9 showed PSA decrease from baseline.
- Trial powered for 45% PFS improvement; actual PFS far exceeded CARD trial benchmark of 3.7-6.7 months.
- No Grade 3/4 toxicities observed; ENV105 well tolerated with standard supportive care.
- Phase 2 trial enrolling at Cedars-Sinai, City of Hope, Huntsman Cancer Center; KOL event held Sept 18.

## SEC filing metadata
- accession: 0001493152-25-013975
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315225013975/0001493152-25-013975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315225013975/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-013975
- JSON: https://secwatch.observer/filing/0001493152-25-013975.json
- Plain text: https://secwatch.observer/filing/0001493152-25-013975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.